These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 11416667)

  • 1. Target Organ Damage in Hypertension.
    Odama U; Bakris G
    J Clin Hypertens (Greenwich); 2000 Oct; 2(5):312-318. PubMed ID: 11416667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maximizing Cardiorenal Benefit in the Management of Hypertension: Achieve Blood Pressure Goals.
    Bakris GL
    J Clin Hypertens (Greenwich); 1999 Oct; 1(2):141-147. PubMed ID: 11416606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension-Do These Differ From the U.S. Recommendations? Which Guidelines Should the Practicing Physician Follow?
    Moser M
    J Clin Hypertens (Greenwich); 1999 Jul; 1(1):48-54. PubMed ID: 11416593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ESH-ESC guidelines for the management of hypertension.
    Erdine S; Ari O; Zanchetti A; Cifkova R; Fagard R; Kjeldsen S; Mancia G; Poulter N; Rahn KH; Rodicio JL; Ruilope LM; Staessen J; van Zwieten P; Waeber B; Williams B
    Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 2004 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I--Blood pressure measurement, diagnosis and assessment of risk.
    Hemmelgarn BR; Zarnke KB; Campbell NR; Feldman RD; McKay DW; McAlister FA; Khan N; Schiffrin EL; Myers MG; Bolli P; Honos G; Lebel M; Levine M; Padwal R;
    Can J Cardiol; 2004 Jan; 20(1):31-40. PubMed ID: 14968141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How Low Should We Treat Blood Pressure and Why?
    Weir MR
    J Clin Hypertens (Greenwich); 1999 Nov; 1(3):199-208. PubMed ID: 11416613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Twelve shifting paradigms in diabetic renal disease and hypertension.
    Mogensen CE
    Diabetes Res Clin Pract; 2008 Nov; 82 Suppl 1():S2-9. PubMed ID: 18947897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypertension in Type II Diabetes: Update on Therapy.
    Sowers JR
    J Clin Hypertens (Greenwich); 1999 Jul; 1(1):41-47. PubMed ID: 11416592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of hypertension in chronic kidney disease.
    Toto RD
    Semin Nephrol; 2005 Nov; 25(6):435-9. PubMed ID: 16298269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New treatment guidelines for a patient with diabetes and hypertension.
    Mogensen CE
    J Hypertens Suppl; 2003 Mar; 21(1):S25-30. PubMed ID: 12769164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Multiple Drug Therapy for Controlling Hypertension in African Americans.
    Weir MR
    J Clin Hypertens (Greenwich); 2000 Mar; 2(2):99-108. PubMed ID: 11416633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
    Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C;
    Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are current strategies for treating hypertension effective?
    Sica DA
    J Clin Hypertens (Greenwich); 2003; 5(3 Suppl 2):23-32. PubMed ID: 12826767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microalbuminuria: a common, independent cardiovascular risk factor, especially but not exclusively in type 2 diabetes.
    Donnelly R; Yeung JM; Manning G
    J Hypertens Suppl; 2003 Mar; 21(1):S7-12. PubMed ID: 12769161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy.
    Khan NA; McAlister FA; Lewanczuk RZ; Touyz RM; Padwal R; Rabkin SW; Leiter LA; Lebel M; Herbert C; Schiffrin EL; Herman RJ; Hamet P; Fodor G; Carruthers G; Culleton B; DeChamplain J; Pylypchuk G; Logan AG; Gledhill N; Petrella R; Campbell NR; Arnold M; Moe G; Hill MD; Jones C; Larochelle P; Ogilvie RI; Tobe S; Houlden R; Burgess E; Feldman RD;
    Can J Cardiol; 2005 Jun; 21(8):657-72. PubMed ID: 16003449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microalbuminuria and cardiovascular risk.
    Karalliedde J; Viberti G
    Am J Hypertens; 2004 Oct; 17(10):986-93. PubMed ID: 15485765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reaching for aggressive blood pressure goals: role of angiotensin receptor blockade in combination therapy.
    Milani RV
    Am J Manag Care; 2005 Sep; 11(7 Suppl):S220-7. PubMed ID: 16180960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular permeability, blood pressure, and organ damage in primary hypertension.
    Viazzi F; Leoncini G; Ratto E; Parodi A; Falqui V; Conti N; Tomolillo C; Ravera G; Deferrari G; Pontremoli R
    Hypertens Res; 2008 May; 31(5):873-9. PubMed ID: 18712042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.